[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Metagenomi Therapeutics Inc (MGX)

Metagenomi Therapeutics Inc (MGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 44,199
  • Shares Outstanding, K 37,777
  • Annual Sales, $ 25,210 K
  • Annual Income, $ -87,870 K
  • EBIT $ -93 M
  • EBITDA $ -91 M
  • 60-Month Beta 0.67
  • Price/Sales 1.77
  • Price/Cash Flow N/A
  • Price/Book 0.39

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.74
  • Number of Estimates 2
  • High Estimate $-0.73
  • Low Estimate $-0.75
  • Prior Year $-0.55
  • Growth Rate Est. (year over year) -34.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1281 +3.27%
on 09/01/26
1.2600 -7.54%
on 08/21/26
-0.0250 (-2.10%)
since 07/31/26
3-Month
1.1281 +3.27%
on 09/01/26
1.3800 -15.58%
on 06/03/26
-0.1650 (-12.41%)
since 06/02/26
52-Week
1.1281 +3.27%
on 09/01/26
3.9500 -70.51%
on 10/16/25
-0.6550 (-35.99%)
since 09/02/25

Most Recent Stories

More News
Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference

WFC : 89.29 (+2.59%)
MGX : 1.1600 (-0.85%)
Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference

EMERYVILLE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies...

MGX : 1.1600 (-0.85%)
Metagenomi Therapeutics: Q2 Earnings Snapshot

Metagenomi Therapeutics: Q2 Earnings Snapshot

MGX : 1.1600 (-0.85%)
Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

Remains on track to submit investigational new drug (IND) application in 4Q 2026 for the global clinical program of MGX-001 for the treatment of hemophilia A $120.7 million in cash, cash equivalents,...

MGX : 1.1600 (-0.85%)
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be limited time to enforce your rights.  

MGX : 1.1600 (-0.85%)
Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference

EMERYVILLE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to...

MGX : 1.1600 (-0.85%)
Metagenomi Therapeutics: Q1 Earnings Snapshot

Metagenomi Therapeutics: Q1 Earnings Snapshot

MGX : 1.1600 (-0.85%)
Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

On track for regulatory submission of MGX-001 to advance global clinical program, including investigational new drug application (“IND”) in 4Q 2026 Publication in Nature Structural & Molecular...

MGX : 1.1600 (-0.85%)
Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results...

MGX : 1.1600 (-0.85%)
Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency

EMERYVILLE, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies...

MGX : 1.1600 (-0.85%)

Business Summary

Metagenomi Therapeutics Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. Metagenomi Therapeutics Inc., formerly known as Metagenomi Inc., is based in EMERYVILLE, Calif.

See More

Key Turning Points

3rd Resistance Point 1.2592
2nd Resistance Point 1.2246
1st Resistance Point 1.1973
Last Price 1.1600
1st Support Level 1.1354
2nd Support Level 1.1008
3rd Support Level 1.0735

See More

52-Week High 3.9500
Fibonacci 61.8% 2.8720
Fibonacci 50% 2.5391
Fibonacci 38.2% 2.2061
Last Price 1.1600
52-Week Low 1.1281

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.